SEATTLE, May 05, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global sarcoma biopsy market was valued at US$ 192.55 million in 2019 and is expected to exhibit a CAGR of 2.8% during the forecast period (2020-2027).
Key Trends and Analysis of the Global Sarcoma Biopsy Market:
The global sarcoma biopsy market is expected to witness significant growth over the forecast period, owing to increasing regulatory approval for biopsy devices. For instance, in 2018, TransMed7, LLC received the U.S. FDA 510(k) application approval for its SpeedBird platform of soft tissue biopsy devices. The SpeedBird platform is based on TransMed7’s patented Zero5TM work element composed of a fused, single element constructed from 3 hypotubes and forming rotating twin cutter blades.
Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/3819
Furthermore, increasing prevalence of osteosarcoma is expected to drive the market growth during the forecast period. For instance, according to the American Cancer Society, 2020, about 800 to 900 new cases of osteosarcoma are diagnosed in the U.S. each year, with about half of these occurs in children and teenagers. According to American Cancer Society estimates, the incidence of synovial sarcoma in the U.S. for 2018 is expected to be 13,040 patients out of which 7,370 in males and 5,670 in females.
Key players in the market are also focused on technological advancements in the biopsy field. For instance, in 2017, Strand Gene Word launched liquid biopsy tests for cancer.
Read Report Summary @ https://www.coherentmarketinsights.com/market-insight/sarcoma-biopsy-market-3819
Key Market Takeaways:
- Technologically advanced biopsy guidance systems such as vacuum assisted guns are gaining popularity among patients and healthcare providers. Moreover, rising prevalence of cancer is further expected to boost growth of the market. According to the World Health Organization (WHO) 2016, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and is classified as a rare disease, which accounts for around 17-20% of all the cases (2.5 per Mn population) of sarcoma.
- Moreover, health care sector in the emerging economies is experiencing substantial growth over last decade, in order to improve the quality of health infrastructure and address health service capacity gaps, which is expected to drive the market growth over the forecast period. For instance, according to World Bank data 2013, health care expenditure in MENA is estimated to reach US$ 144 billion by 2020.
Key players operating in the global sarcoma biopsy market include—
C. R. Bard, Inc., Becton, Dickinson and Company, Argon Medical Devices, InVivo Therapeutics Corporation, Cook Medical Incorporated, UROMED, and Sterylab
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3819
Market Segmentation:
- Global Sarcoma Biopsy Market, By Product Type:
- Reusable Devices
- Disposable Devices
- Global Sarcoma Biopsy Market, By End User:
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Centers
- Global Sarcoma Biopsy Market, By Region:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- North America
Related Topics:
SLEEP TESTING SERVICES MARKET
Polysomnography is type of test conducted to diagnose sleep disorders. Sleep study is conducted to diagnose various sleep disorder conditions such as sleep apnea, periodic limb movement disorder, Narcolepsy, REM, sleep behavior disorder, unexplained chronic insomnia and others. Obesity is associated with modification in several comorbidities, including sleep-related disorders.
Read more @ https://www.coherentmarketinsights.com/market-insight/sleep-testing-services-market-3764
PARP INHIBITOR BIOMARKERS MARKET
PARP inhibitors are drugs which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitor biomarker are developed for diagnosis and treatment of several diseases, and the most important one is cancer. Several types of cancers rely on PARP enzymes than regular cells which make these inhibitors an effective mode for treating cancers. PARP inhibitors are used to treat a subset of ovarian and breast cancer.
Read more @ https://www.coherentmarketinsights.com/market-insight/parp-inhibitor-biomarkers-market-3762
NORTH AMERICA OUTBOUND MEDICAL TOURISM SERVICES MARKET
Outbound medical tourism is defined as traveling of patients outside their country to avail various medical treatments. The preferred countries by U.S. outbound medical patients for weight loss treatment are Jordan, Poland, India, and Mexico. Increasing rate of uninsured population is expected to boost growth of North America outbound medical tourism services market over the forecast period.